About Omnia Biologics
Omnia Biologics is a Healthcare company based in Rockville (United States) founded in 2001, and was acquired by Vigene Biosciences in November 2016. Process development and manufacturing services for biologics are provided. Omnia Biologics has raised $25.4 million across 2 funding rounds from investors including Vigene Biosciences and Medipost. Omnia Biologics offers products and services including Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO and Biologics. Its legal entity is OmniaBio Inc. Its competitors include KBI Biopharma, Aldevron and Arranta Bio; 2 of its 3 listed competitors have raised funding.
Company details
Omnia Biologics was founded in 2001 in Rockville, United States, focusing on the biologics sector. Non-GMP and GMP facilities were utilized for process development from preclinical stages through Phase III manufacturing. Expertise encompassed adenovirus, lentivirus, retrovirus, AAV, VLP, and other viral platforms. Services included manufacturing, process development, cell and virus banking, and aseptic filling. Orders are no longer accepted, with diversions directed to Vigene Biosciences.
- Headquarters Rockville, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website omniabio.com
- Social LinkedIn
- Acquired by Vigene Biosciences (Nov 2016)
- Legal Name Omniabio Inc
- Total Equity Funding$25.4M (USD)
in 2 rounds
- Latest Funding Round$23.9M (USD), Series B
May 2022
- InvestorsVigene Biosciences
& 1 more
- Acquired byVigene Biosciences
(Nov 2016)
Products & Services of Omnia Biologics
Omnia Biologics offers a comprehensive portfolio of products and services, including Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing.
Optimizes processes for cell and gene therapy production.
Develops assays for quality control in therapies.
Delivers compliant manufacturing for cell therapies.
Supports large-scale therapy production and delivery.
Funding Insights of Omnia Biologics
Omnia Biologics has successfully raised a total of $25.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $23.9 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.4M
- Total Rounds 2
- Last Round Series B — $23.9M
- First Round $1.5M
(May 2006)
- Investors Count 1
All 2 funding rounds of Omnia Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | $23.9M | Series B | – | Medipost | – |
| May 2006 | $1.5M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Omnia Biologics
Omnia Biologics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Vigene Biosciences and Medipost.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| medi-post.com | ||||
Research reagents for drug discovery and functional genomics are developed. | 2012 | vigenebio.com | Rockville, United States |
Investor details for Omnia Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Omnia Biologics
22 people are tracked at Omnia Biologics (12 in leadership, 10 in team).
| Name | Role | Group |
|---|---|---|
Tony Rotunno | Site Head | Leadership |
Zahra Sheikholeslami | Associate Director | Leadership |
Kelly Tayal Chrl | Human Resources Director | Leadership |
Lise Munsie | Vp, Ipsc Technology Platform | Leadership |
Mitchel Sivilotti | Chief Executive Officer | Leadership |
Michael Israels | Director And CFO | Leadership |
Joanne Woodley-Smith | Director, Facilities And Engineering | Leadership |
Shivali Joshi | Associate Director - Analytics | Leadership |
Jeff Miller | Chief Legal Officer | Leadership |
Anthony Rotunno | SVP Gm/site Head | Leadership |
David Farr | Director, Business Development | Leadership |
Valorie Tutt | Director Legal Risk And Compliance | Leadership |
Shaunelle V. | Manager External Quality | Team |
Sabrina Sam | Quality Assurance Associate | Team |
Jennifer Patterson | Senior Manager Quality Control | Team |
Jessica Bond | Senior Manager, Talent Acquisition | Team |
Michael Lu | Business Process Manager - Scm, IT | Team |
Erica Ciaramella | Human Resources Generalist | Team |
Pooja Pushparaj | Associate Scientist III | Team |
Nikhil Desai | Senior Compliance Specialist | Team |
2 more people are available in the full profile.
Complete people profiles for Omnia Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Omnia Biologics
4 dated milestones of Omnia Biologics across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Omnia Biologics is founded.
- Funding First funding round of $1.5M.
- Exit Acquired by Vigene Biosciences.
- Funding Latest funding round, Series B, of $23.9M.
Competitors of Omnia Biologics
Omnia Biologics has 3 listed competitors in our database, 2 of them funded. They include KBI Biopharma, Aldevron and Arranta Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kbibiopharma.com | 1996 | Durham, United States | $17M | 1,243 | Provider of protein formulation, process & cell line development, and cGMP services | |
| aldevron.com | 1998 | Fargo, United States | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | ||
| arrantabio.com | 2019 | Watertown, United States | $82M | Developer of therapeutics for microbiome based diseases |
Detailed competitors of Omnia Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Omnia Biologics
The website of Omnia Biologics (omniabio.com) receives about 6.7K visits a month and ranks #4,275,375 among all websites worldwide, #5,267 in Biotechnology and Pharmaceuticals.
- Monthly visits6.7K
▲ 52.9% vs previous month
- Unique visitors1.9K
per month
- Global rank#4,275,375
among all websites
- Category rank#5,267
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.5
- Average visit20 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Omnia Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ccrm.ca | 100% | #3,718,695 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Omnia Biologics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Omnia Biologics
Complete news archive for Omnia Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omnia Biologics
Omnia Biologics was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Omnia Biologics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Omnia Biologics is a funded company, having raised a total of $25.4M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on May 2006.
Omnia Biologics was founded in 2001 in Rockville, United States, focusing on the biologics sector. Non-GMP and GMP facilities were utilized for process development from preclinical stages through Phase III manufacturing. Expertise encompassed adenovirus, lentivirus, retrovirus, AAV, VLP, and other viral platforms. Services included manufacturing, process development, cell and virus banking, and aseptic filling. Orders are no longer accepted, with diversions directed to Vigene Biosciences.
Omnia Biologics's top competitors include KBI Biopharma, Aldevron and Arranta Bio.
Omnia Biologics offers Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing.
Omnia Biologics has 2 investors. Key investors include Vigene Biosciences, and Medipost.
Omnia Biologics operates through Omniabio Inc.
Yes. Omnia Biologics was acquired by Vigene Biosciences in November 2016.